Synthesis, DNA binding, hemolysis assays and anticancer studies of copper(II), nickel(II) and iron(III) complexes of a pyrazoline-based ligand

Future Medicinal Chemistry

Volumn 5, Issue 2, 2013, Pages 135-146

  Saleem, Kishwar ^a   Wani, Waseem A ^a   Haque, Ashanul ^a   Lone, Mohamad Nadeem ^a   Hsieh, Ming Fa ^b   Jairajpuri, Mohamad Aman ^a   Ali, Imran ^a  

^a JAMIA MILLIA ISLAMIA CENTRAL UNIVERSITY   (India)

^b CHUNG YUAN CHRISTIAN UNIVERSITY   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

3 (4,5 DIMETHYL 2 THIAZOLYL) 2,5 DIPHENYLTETRAZOLIUM BROMIDE; ANTINEOPLASTIC AGENT; COPPER COMPLEX; DNA; IRON COMPLEX; NICKEL COMPLEX; PYRAZOLINE DERIVATIVE;

ARTICLE; CELL STRAIN MCF 7; CLAISEN CONDENSATION; COMPUTER MODEL; CONTROLLED STUDY; DNA BINDING; DRUG SYNTHESIS; HUMAN; HUMAN CELL; PRIORITY JOURNAL;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; COPPER; DNA; HEMOLYSIS; HUMANS; IRON COMPOUNDS; LIGANDS; MCF-7 CELLS; NICKEL; PROTEIN BINDING; PYRAZOLES; RABBITS;

EID: 84873320922     PISSN: 17568919     EISSN: 17568927     Source Type: Journal    
DOI: 10.4155/fmc.12.201     Document Type: Article

References (47)

1. Ali I, Wani WA, Saleem K. Cancer scenario in India with future perspectives. Cancer Ther. 8, 56-70 (2011).
2. Ali I, Rahis-Uddin, Saleem K, Aboul-Enein HY, Rather A. Social aspects of cancer genesis. Cancer Ther. 8, 6-14 (2011).
3. Ali I, Rahis-Uddin, Saleem K, Rather MA, Wani WA, Haque A. Advances in nano drugs for cancer chemotherapy. Curr. Cancer Drug Targets 11(2), 135-146 (2011).
4. Ali I, Wani WA, Saleem K, Haque A. Platinum complexes: a hope for future cancer chemotherapy. Anticancer Agents Med. Chem. 13(2), 296-306 (2013).
5. Shaaban MR, Mayhoub AS, Farag MA. Recent advances in the therapeutic applications of pyrazolines. Expert Opin. Ther. Pat. 22(3), 253-291 (2012).
6. Rostom SA, Badr MH, Abd El Razik HA, Ashour HM, Abdel Wahab AE. Synthesis of some pyrazolines and pyrimidines derived from polymethoxy chalcones as anticancer and antimicrobial agents. Arch. Pharm. (Weinheim) 344(9), 572-587 (2011).
7. Abdel-Aziz M, Aly OM, Khan SS, Mukherjee K, Bane S. Synthesis, cytotoxic properties and tubulin polymerization inhibitory activity of novel 2-pyrazoline derivatives. Arch. Pharm. (Weinheim) 345(7), 535-548 (2012).
8. Havrylyuk D, Kovach N, Zimenkovsky B, Vasylenko O, Lesyk R. Synthesis and anticancer activity of isatin-based pyrazolines and thiazolidines conjugates. Arch. Pharm. (Weinheim) 344(8), 514-522 (2011).
9. Lv PC, Li DD, Li QS, Lu X, Xiao ZP, Zhu HL. Synthesis, molecular docking and evaluation of thiazolyl-pyrazoline derivatives as EGFR TK inhibitors and potential anticancer agents. Bioorg. Med. Chem. Lett. 21(18), 5374-5377 (2011).
10. Ruiz-Azuara L, Bravo-Gomez ME. Copper compounds in cancer chemotherapy. Curr. Med. Chem. 17(31), 3606-3615 (2010).
11. Tan SJ, Yan YK, Lee PPF, Lim KH. Copper, gold and silver compounds as potential new anti-tumor metallodrugs. Future Med. Chem. 2(10), 1591-1608 (2010).
12. Ali I, Wani WA, Saleem K, Wesselinova D. Syntheses, DNA binding and anticancer profiles of l-glutamic acid ligand and its copper(II) and ruthenium(III) complexes. Med. Chem. 9(1), 11-21 (2013).
13. Ali I, Saleem K, Wesselinova D, Haque A. Synthesis, DNA binding, hemolytic and anticancer assays of curcumin I based ligands and their ruthenium(III) complexes. Med. Chem. Res. doi:10.1007/s00044-012-0133-8 (2012).
14. Matkar SS, Wrischnik LA, Jones PR, Hellmann-Blumberg U. Two closely related nickel complexes have different effects on DNA damage and cell viability. Biochem. Biophys. Res. Commun. 343(3), 754-761 (2006).
15. Afrasiabi Z, Sinn E, Lin W, Campana YMC, Padhye S. Nickel (II) complexes of naphthaquinone thiosemicarbazone and semicarbazone: Synthesis, structure, spectroscopy, and biological activity. J. Inorg. Biochem. 99(7), 1526-1531 (2005). (Pubitemid 40804962)
16. Buschini A, Pinelli S, Pellacani C et al. Synthesis, characterization and deepening in the comprehension of the biological action mechanisms of a new nickel complex with antiproliferative activity. J. Inorg. Biochem. 103(5), 666-677 (2009).
17. Maier PK, Neuse HKEW. Ferricenium complexes: a new type of water-soluble antitumor agent. J. Cancer Res. Clin. Oncol. 108(3), 336-340 (1984).
18. Hillard E, Vessieres A, Thouin L, Jaouen G, Amatore C. Ferrocene-mediated proton-coupled electron transfer in a series of ferrocifen-type breast cancer drug candidates. Angew. Chem. 118(2), 291-296 (2006).
19. Hillard E, Vessieres A, Le Bideau F et al. A series of unconjugated ferrocenyl phenols: prospects as anticancer agents. Chem. Med. Chem. 1(5), 551-559 (2006). (Pubitemid 43759766)
20. Duivenvoorden WCM, Liu Y, Schatte G, Kraatz HB. Synthesis of redox-active ferrocene pyrazole conjugates and their cytotoxicity in human mammary adenocarcinoma MCF-7 cells. Inorg. Chim. Acta 358(11), 3183-3189 (2005). (Pubitemid 40777900)
21. Ramakrishnan S, Suresh E, Riyasdeen A, Akbarsha MA, Palaniandavar M. DNA binding, prominent DNA cleavage and efficient anticancer activities of tris(diimine) iron(II)complexes. Dalton Trans. 40(4), 3524-3536 (2011).
22. Sanner MF. Python: a programming language for software integration and development. J. Mol. Graph Model 17 (1), 57-61 (1999). (Pubitemid 30029318)
23. Morris GM, Goodsell GS, Halliday RS et al. Automated docking using a Lamarckian genetic algorithm and an empirical binding free energy function. J. Comput. Chem. 19(14), 1639-1662 (1998). (Pubitemid 128590223)
24. Pettersen EF, Goddard TD, Huang CC et al. UCSF Chimera - a visualization system for exploratory research and analysis. J. Comput. Chem. 25(13), 1605-1612 (2004).
25. Reichmann MF, Rice SA, Thomas CA, Doty P. A further examination of the molecular weight and size of desoxypentose nucleic acid. J. Am. Chem. Soc. 76(11), 3047-3053 (1954).
26. ASTM F756-00. Standard Practice for Assessment of Hemolytic Properties of Materials. ASTM International, West Conshohocken, PA, USA. doi:10.1520/F0756-00 (2000).
27. Mosman T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J. Immunol. Methods 65(1-2), 55-63 (1983).
28. Chohan ZH, Pervez H, Rauf A, Khan KM, Supuran CT. Isatins-derived antibacterial and antifungal compounds and their transition metal complexes. J. Enz. Inhib. Med. Chem. 19(5), 417-423 (2004). (Pubitemid 40045502)
29. Geary WJ. The use of conductivity measurements in organic solvents for the characterisation of coordination compounds. Coord. Chem. Rev. 7, 81-122 (1971).
30. Krishna CH, Mahapatra CM, Dash AK. 4-5 and 6-coordinate complexes of copper (II) with substituted imidazoles. J. Inorg. Nucl. Chem. 39(7), 1253-1258 (1977).
31. Sarkar S, Dey K. Synthesis and spectroscopic characterization of some transition metal complexes of a new hexadentate N(2)S(2) O(2)Schiff base ligand. Spectrochim. Acta Part A 62(1-3), 383-393 (2005). (Pubitemid 41562632)
32. Chaudhary A, Singh RV. Synthetic, spectroscopic and toxicological aspects of novel eighteen to twenty two membered tetraaza macrocycles and their bivalent manganese complexes. Ind. J. Chem. 43, 2529-2535 (2004). (Pubitemid 40128730)
33. Kemp W. Organic Spectroscopy. Macmillan Press Ltd, London, UK (1975).
34. Kung A, Pieper T, Wissiack R, Rosenberg E, Keppler BK. Hydrolysis of the tumor-inhibiting ruthenium(III) complexes HIm trans-[RuCl4(im)2] and Hind trans- [RuCl4(ind)2] investigated by means of HPCE and HPLC-MS. J. Biol. Inorg. Chem. 6(3), 292-299 (2001). (Pubitemid 32823962)
35. Groessl M, Hartinger CG, Dyson PJ, Keppler BK. CZE-ICP-MS as a tool for studying the hydrolysis of ruthenium anticancer drug candidates and their reactivity towards the DNA model compound dGMP. J. Inorg. Biochem. 102(5-6), 1060-1065 (2008).
36. Bacac M, Hotze ACG, van der Schilden K et al. The hydrolysis of the anti-cancer ruthenium complex NAMI-A affects its DNA binding and antimetastatic activity: an NMR evaluation. J. Inorg. Biochem. 98(2), 402-412 (2004). (Pubitemid 38083159)
37. Mathur S, Tabassum S. Template synthesis of novel carboxamide dinuclear copper (II) complex: spectral characterization and reactivity towards calf-thymus DNA. Biometals 21(3), 299-310 (2008). (Pubitemid 351579745)
38. Parveen S, Arjmand F. De novo design, synthesis and spectroscopic characterization of chiral benzimidazole-derived amino acid Zn(II) complexes: development of tryptophan-derived specific hydrolytic DNA artificial nuclease agent. Spectrochim. Acta Part A 85(1), 53-60 (2012).
39. Xu ZD, Liu H, Xiao SL, Yang M, Bu XH. Synthesis, crystal structure, antitumor activity and DNA-binding study on the Mn(II) complex of 2H-5-hydroxy-1,2,5-oxadiazo[3,4- f ]1,10-phenanthroline. J. Inorg. Biochem. 90(3-4), 79-84 (2002). (Pubitemid 34522069)
40. Wang Y, Yan ZY. Synthesis, characterization and DNA-binding properties of three 3d-transition metal complexes of the Schiff base derived from diethenetriamine with PMBP. Tran. Metal Chem. 30(7), 902-906 (2005). (Pubitemid 41367243)
41. Marmur J. Procedure for isolation of deoxyribonucleic acid from microorganism. J. Mol. Biol. 3(2), 208-214 (1961).
42. Peng B, Chao H, Sun B, Li H, Gao F, Ji L. DNA interactions of a functionalized ruthenium(II) mixed-polypyridyl complex [Ru(bpy)2ppd]2+. J. Inorg. Biochem. 100(9), 1487-1494 (2006). (Pubitemid 44209186)
43. Li Q, Yang P, Wang H, Guo M. Diorganotin(IV) antitumor agent. (C2H5)2SnCl2 (phen)/nucleotides aqueous and solid-state coordination chemistry and its DNA binding studies. J. Inorg. Biochem. 64(3), 181-195 (1996). (Pubitemid 26357155)
44. Quiroga AG, Perez JM, Lopez-Solera I et al. Binuclear chloro-bridged palladated and platinated complexes derived from p-isopropylbenzaldehyde thiosemicarbazone with cytotoxicity against cisplatin resistant tumor cell lines. J. Inorg. Biochem. 69(4) 275-281 (1998). (Pubitemid 28294535)
45. Chauhan M, Arjmand F. Chiral and achiral macrocyclic copper(II) complexes: synthesis, characterization, and comparative binding studies with calf-thymus DNA. Chem. Biodiv. 3(6), 660-676 (2006). (Pubitemid 44018220)
46. Christie MS, Kenneth LR, David BW. Assessing toxicity of fine and nanoparticles: comparing in vitro measurements to in vivo pulmonary toxicity profiles. Toxicol. Sci. 97(1), 163-180 (2007).
47. RCSB Protein Bank. www.rcsb.org/pdb